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Abstract
Background Pre-eclampsia is a pregnancy complication
affecting both mother and fetus. Although there is no
proven effective method to prevent pre-eclampsia, early
identification of women at risk of pre-eclampsia could
enhance appropriate application of antenatal care, man-
agement and treatment. Very little is known about the cost
effectiveness of these and other tests for pre-eclampsia,
mainly because there is no clear treatment path. The aim of
this study was to provide a comprehensive overview of the
existing evidence on the health economics of screening,
diagnosis and treatment options in pre-eclampsia.
Methods We searched three electronic databases
(PubMed, EMBASE and the Cochrane Library) for studies
on screening, diagnosis, treatment or prevention of pre-
eclampsia, published between 1994 and 2014. Only full
papers written in English containing complete economic
assessments in pre-eclampsia were included.
Results From an initial total of 138 references, six papers
fulfilled the inclusion criteria. Three studies were on the
cost effectiveness of treatment of pre-eclampsia, two of
which evaluated magnesium sulphate for prevention of
seizures and the third evaluated the cost effectiveness of
induction of labour versus expectant monitoring. The other
three studies were aimed at screening and diagnosis, in
combination with subsequent preventive measures. The
two studies on magnesium sulphate were equivocal on the
cost effectiveness in non-severe cases, and the other study
suggested that induction of labour in term pre-eclampsia
was more cost effective than expectant monitoring. The
screening studies were quite diverse in their objectives as
well as in their conclusions. One study concluded that
screening is probably not worthwhile, while two other
studies stated that in certain scenarios it may be cost
effective to screen all pregnant women and prophylacti-
cally treat those who are found to be at high risk of
developing pre-eclampsia.
Discussion This study is the first to provide a compre-
hensive overview on the economic aspects of pre-
eclampsia in its broadest sense, ranging from screening
to treatment options. The main limitation of the present
study lies in the variety of topics in combination with the
limited number of papers that could be included; this
restricted the comparisons that could be made. In con-
clusion, novel biomarkers in screening for and diag-
nosing pre-eclampsia show promise, but their accuracy is
a major driver of cost effectiveness, as is prevalence.
Universal screening for pre-eclampsia, using a bio-
marker, will be feasible only when accuracy is signifi-
cantly increased.
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Key Points for Decision Makers
In the field of pre-eclampsia, very few cost-
effectiveness studies have been performed.
Because of substantial variations in the aims and
results of these studies, no unequivocal conclusions
can be drawn as to what constitutes cost-effective
care in pre-eclampsia.
Limited data exist to support the cost effectiveness of
biomarkers for pre-eclampsia.
1 Introduction
Pre-eclampsia is a pregnancy complication that is typically
characterized by new-onset hypertension and proteinuria
after 20 weeks of gestation and affects both mother and
fetus. The pathogenesis of pre-eclampsia is not well
understood, and the only treatment proven to be effective is
delivery. Accurate incidence figures are difficult to obtain,
and the incidence varies between countries, but it is
believed that worldwide, 3–5 % of pregnant women are
affected [1]. In economically poor regions, where there is
often only very limited antenatal and intrapartum care, pre-
eclampsia is a severely life-threatening condition, reflected
by the fact that it is one of the leading causes of maternal
mortality [2]. Pre-eclampsia is also a leading cause
(23.6 %) of perinatal death in economically poor countries
[3]. In economically rich countries, pre-eclampsia is less
lethal in an absolute sense, although the condition is
responsible for around 13 % of maternal deaths [2];
enhanced surveillance and diagnostic possibilities enable
more timely and better detection, which, in turn, leads to
higher rates of iatrogenic preterm birth, and pre-eclampsia
is responsible for occupancy of up to 20 % of neonatal
intensive care unit cots [4]. Although there is no proven
effective method to prevent pre-eclampsia, screening and
early identification of women at risk of pre-eclampsia
could enable appropriate application of antenatal care,
management and treatment. Screening includes testing,
usually in the first half of pregnancy, to identify women at
increased risk of pre-eclampsia [5]. At present, pre-
eclampsia screening consists of assessing clinical risk
factors such as age, body mass index (BMI) and family
history, in combination with an ultrasound scan at
20 weeks. However, an international cohort project deter-
mined that the predictive power of clinical risk factors was
modest [6]. Recently, several maternal serum markers have
been assessed as novel candidates for predicting pre-
eclampsia. Placental growth factor (PIGF), pregnancy-
associated plasma protein A (PAPP-A) [7–9], first trimester
placental protein-13 [10, 11] and soluble fms-like tyrosine
kinase-1 (sFlt-1) [12] are some of the potential biomarkers
for detecting the development of pre-eclampsia. However,
a systematic review by Kleinrouweler et al [13]. on the
accuracy of PIGF and sFLT-1 (among other tests) con-
cluded that test accuracy was too poor to adequately predict
pre-eclampsia in clinical practice, although the tests might
be useful when incorporated into multivariable prediction
models. Kenny et al [14]. combined clinical factors and
measurements of previously reported biomarkers for pre-
eclampsia risk in women recruited for the Screening for
Pregnancy Endpoints (SCOPE) study of low-risk nulli-
parous women; combining multiple biomarkers and clini-
cal and ultrasound data again provided only a modest
prediction of pre-eclampsia. Future developments seem
likely to rely on untargeted ‘-omic’ discovery strategies
that appear to show promise [15, 16]. Once patients have
been identified as being at high risk of developing pre-
eclampsia, treatment options for prevention are relatively
limited. The American College of Obstetricians and
Gynecologists (ACOG) and the World Health Organization
(WHO) recommend daily low-dose aspirin (60–80 mg)
[17, 18]. In addition, the WHO recommends calcium
(1.5–2.0 g per day), especially in areas where dietary cal-
cium intake is low [18]. However, the quality of the evi-
dence underlying these recommendations is only moderate.
Explicitly not recommended are vitamin C and E supple-
mentation, restriction of dietary salt intake, and bedrest
[17, 18]. Treatment for patients who have developed pre-
eclampsia or eclampsia mainly consists of intensified
management, magnesium sulphate for prevention of
eclampsia and convulsions, and, at a certain point, induc-
tion of labour [17, 18]. Naturally, induction of labour
necessitates hospital admission, and in some cases inten-
sified management may also require inpatient monitoring.
Compared with the extensive clinical research, the liter-
ature on economic evaluations in pre-eclampsia is rather
limited. As the scarcity of resources contrasts with the
seemingly ever-increasing possibilities in diagnostic, treat-
ment and preventive techniques, it is essential to analyse the
association between the resources used and the related
effects of any given medical intervention [19]. Health eco-
nomic assessments can provide relevant insights into safe,
effective and efficient health care for health care decision
makers at all levels [20, 21]. While economic evaluations
address the efficiency of two or more alternatives in terms of
both costs and health consequences, often expressed as the
incremental cost per quality-adjusted life-year (QALY)
gained, the purpose of budget impact analysis (BIA) is to
investigate the financial impact of introducing new health
care intervention(s) in terms of estimating affordability
instead of assessing value for money [22].
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This study is intended to provide, by means of a sys-
tematic review, a comprehensive insight into the existing
health economic evidence (either economic evaluations or
BIAs) of screening, diagnosis and treatment options for
pre-eclampsia.
2 Methods
2.1 Search Strategy
Three electronic databases (PubMed, EMBASE and the
Cochrane Library) were examined in March 2015 to
investigate eligible reports/studies of screening, diagnosis,
treatment and prevention of pre-eclampsia in the last
20 years (1994–2014). The search terms for all databases
were (pre-eclampsia OR ‘pre eclampsia’) AND (screening
OR diagnosis*) AND (prevent* OR intervention) AND
(treatment OR manage*) AND (‘cost of illness’ OR ‘cost
analysis’ OR ‘cost effectiveness’ OR ‘cost benefit’ OR
‘cost utility’ OR ‘economic evaluation’ OR ‘economic
analysis’ OR ‘budget impact’). We included only studies
that were performed in humans. Papers not written in
English were excluded. For the Cochrane Library, inclu-
sion was limited to economic evaluations.
2.2 Study Selection and Data Extraction
The initial screening was based on the title and abstract,
followed by a full-text review of the selected articles. In
this review, only complete economic assessments in pre-
eclampsia, classified as economic evaluations and/or BIAs,
were included. Additionally, economic evaluations were
categorized as cost analysis (CA), cost-effectiveness anal-
ysis (CEA), cost–utility analysis (CUA) or cost–benefit
analysis (CBA). Furthermore, studies were included if they
contained a clear description of the methods used. Irre-
trievable references, poster presentations and meeting
abstracts were excluded. For comparability of results
across studies, all costs reported in the included papers
were set to 2014 US dollar (USD) values by using inflation
rates from the World Bank annual consumer price index, as
well as purchasing power parities (PPPs) [23].
2.3 Quality of Reporting
The checklist for appraising the quality of reporting of the
economic evaluation studies was based on the recently
published Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement from the Inter-
national Society For Pharmacoeconomics and Outcomes
Research (ISPOR) Consolidated Health Economic Evalu-
ation Reporting Standards Task Force [24]. The CHEERS
statement is the reporting guidance in economic evaluation,
which incorporates several previously available guidelines,
including the most widely used BMJ checklist [20, 21].
While a checklist for assessing economic evaluation stud-
ies was available and had previously been used extensively,
the methods for appraising BIAs were limited. Therefore,
we used the guidelines on the reporting format for BIAs,
which was based on the Principles of Good Practice for
Budget Impact Analysis published by the ISPOR Task
Force on Good Research Practices—Budget Impact Anal-
ysis [22]. The full CHEERS checklist is shown in Table I
of the Electronic Supplementary Material.
3 Results
3.1 Systematic Search
The search discovered 138 references (41, 85 and 12 arti-
cles from PubMed, EMBASE and the Cochrane Library,
respectively), of which 119 remained after cleaning for
duplicates. Screening of the title and abstract of these
references excluded 111 references, of which 69 were
clearly outside the topic of our research interest, such as
research about other maternal issues in pregnancy (for
example, gestational diabetes mellitus), 39 references were
not economic evaluation studies, one study was outside our
date limits (i.e. published before 1994) and the other two
were not written in English. On the basis of this screening,
eight references met the inclusion criteria. Two of these
were excluded because they were not full papers but con-
ference proceedings. Of the remaining six references, the
full text was screened, resulting in final inclusion of six
references [25–30], as shown in Fig. 1, of which five were
economic evaluation studies and the remaining one was a
BIA. Three studies addressed screening and/or diagnosis
and included subsequent events, whereas the other three
focused on treatment strategies after diagnosis of pre-
eclampsia. In the remainder of this section, each study is
discussed separately, guided by the respective checklists
when applicable. The design and results are addressed, as
well as strengths and limitations. An overview of the main
study characteristics is provided in Table 1, information on
cost categories included and price level is reflected in
Table 2 and a summary of the main findings is presented in
Table 3.
3.2 Summary of Included Studies
3.2.1 Studies on Screening and Diagnosis
Three studies on the topic of screening and diagnosis were
included in the review. Shmueli et al. [27] performed a
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CEA, by means of a model, of routine first-trimester
screening for pre-eclampsia, using placental markers—
placental protein-13 and PIGF—and uterine artery Dop-
pler, as compared with standard care in an Israeli setting.
The detection rates of screening were assumed to be 70 %
for late cases of pre-eclampsia and 90 % for early cases, on
the basis of a previous study [31], with a false negative rate
of 10 %. Screen-positive cases were managed in the same
manner as women with risk factors, i.e. the highest fre-
quency of doctor visits and administration of preventive
measures (any of aspirin, calcium, vitamin D, folic acid
and prenatal multivitamins, or a combination of these). The
time horizon was set at 30 years because follow-up of the
child was considered for the analysis, including the risks of
stillbirth, life expectancy and quality of life up to the age of
30 years [27]. Pre-eclampsia was assumed to be associated
with more preterm births, a higher rate of caesarean section
and a higher rate of admission to a neonatal intensive care
unit, as well as a higher rate of diabetes mellitus type 2 at
the age of 32 years [27, 32]. For input parameters con-
cerning prevalence, time and mode of delivery, and bed
rest prior to delivery, retrospective data from a Haifa
hospital were used. As a consequence, the results were
quite specific to the Israeli setting, but this was made clear
in the paper. The prevalence for the base case was set at
1.7 %, which can be considered rather low given the
2–8 % prevalence reported elsewhere [33, 34]. The
outcomes were the incremental cost per pre-eclampsia case
prevented and the incremental cost per QALY of the off-
spring gained by screening. Univariate sensitivity analysis
was performed on five major parameters: the test cost, the
false positive rate, the pre-eclampsia prevalence, the test’s
detection rate, and the effectiveness of the preventive
measures (i.e. calcium supplementation and low-dose
aspirin). The conclusion of the authors was that screening
for pre-eclampsia is cost effective from the payer per-
spective under various scenarios. The results were sensitive
to changes in each of the parameters that varied in the
sensitivity analysis. In addition, the time horizon was an
important driver of cost effectiveness, in the sense that
extending the time horizon resulted in a more favourable
incremental cost-effectiveness ratio (ICER) for screening
as compared with no screening.
Possible limitations of this study were that there was no
probabilistic sensitivity analysis, even though this is rec-
ommended by guidelines on economic modelling [35] and
is regarded as standard practice nowadays. Also, there was
no report on model validation. Another limitation may
have been the choice of model structure. Given the deci-
sion problem at hand, which concerned calculating long-
term costs and effects, the analysis might have been better
served by using a Markov model, as the choice of a deci-
sion tree seems to have forced the authors to oversimplify
the sequence of events in the long term, resulting in
Fig. 1 Selection of references
in systematic review
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basically only two possible outcomes in the model for
offspring surviving the first year: either diabetes at the age
of 32 years or no diabetes at the age of 32 years.
The study by Meads et al. [26] was a health technology
assessment (HTA) report and incorporated both a
systematic review and a meta-analysis, as well as a cost-
effectiveness model. The aim of the study was to compare
the effectiveness and cost effectiveness of different com-
binations of screening and treatment strategies for pre-
eclampsia in the UK setting. The combinations tested in the
Table 1 Overview of main study characteristics of the economic evaluations included
Study Study design Analysis
Method
and
perspective
Perspective Alternatives compared Time
horizon
Discount rates
(%)
Sensitivity
analysis
Parameters in the sensitivity
analysis
Costs Effects
Screening and diagnosis
Shmueli
[27]
Decision
tree
Payer No screening versus
screening for placental
protein-13, placental
growth factor and
uterine artery Doppler
pulsatility index
30 years 3 3 Best- and
worst-case
scenarios
False positive rate, test cost,
pre-eclampsia prevalence,
test’s detection rate,
effectiveness of preventive
measures (measured as the
proportion of women
whose pre-eclampsia was
not prevented by the
preventive procedures)
Meads
[26]
Decision
tree
Health care
decision
maker
No intervention versus
intervention (in a wide
range of different
testing and treatment
options)
NR NR NR Probabilistic
sensitivity
analysis
Sensitivity and specificity of
the test, prevalence rates,
cost of pre-eclampsia
Hadker
[25]
Decision
tree
UK health
care
payer
Standard pre-eclampsia
diagnostic practice
versus standard
practice ? novel pre-
eclampsia test using
biomarkers
NR NA NA Univariate Pre-eclampsia incidence rate,
sensitivity of current tests,
specificity of current tests,
proportion of patients
stratified as being at high
risk of pre-eclampsia, cost
of the novel pre-eclampsia
test
Treatment
Vijgen
[29]
Trial-
based
CEA
Societal Labour induction
compared with
expectant monitoring
in women with pre-
eclampsia at term
1 year NA NA Univariate Labour and operating theatre
costs, delivery costs,
antepartum admission
costs, neonatal ward
admission costs, no
separation in admission
phase, values of
admissions using lower/
higher unit costs
Simon
[28]
Trial-
based
CEA
Treatment
provider
(hospital)
Magnesium sulphate for
pre-eclampsia in 3
categories of countries
grouped by GNI
\1 year NA NA Univariate Severity of pre-eclampsia,
relative risk of pre-
eclampsia, cost of
magnesium sulphate
Blackwell
[30]
Decision
tree
NR Seizure prophylaxis with
magnesium sulphate
versus control group
with no prophylaxis
30 years 3 0 Univariate Incidence of pre-eclampsia,
incidence of severe pre-
eclampsia, seizure rate
with severe pre-eclampsia,
seizure rate with mild pre-
eclampsia, non-preventable
seizure rate, mortality from
eclampsia, efficacy of
magnesium sulphate
CEA cost-effectiveness analysis, GNI gross national income, NA not applicable, NR not reported
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model were numerous, with these five general strategies
used to represent the approaches: (i) no test and no treat-
ment; (ii) no test and treat all; (iii) test all and no treatment;
(iv) test all and treat only those with positive test result;
and (v) test all and treat all. Only those treatments that were
found (in the meta-analysis) to be unlikely to have a neg-
ative effect (i.e. to result in more cases of pre-eclampsia,
defined as a confidence interval of the odds ratio entirely
\1) were considered in the base-case economic analysis.
These treatments were rest at home, antiplatelets, antioxi-
dants and calcium, and each was combined in the model
with a wide range of tests, e.g. maternal serum human
chorionic gonadotropin (HCG), total fibronectin (FN), total
proteinuria and the Doppler uterine artery pulsatility index.
Estimates of test accuracy used in the model were also
obtained from the project’s meta-analysis. The model
results demonstrated that from the perspective of the UK
National Health Service, the most cost-effective strategy
was to recommend rest for all women without prior testing,
followed by treatment of all women with calcium supple-
mentation, also without initial testing. The preference for a
no-test strategy was caused by the relatively poor accuracy
of the tests as reported in the accompanying systematic
review. In addition, the authors stated that the pattern of
cost effectiveness did not differ between the high-risk
mothers and low-risk mothers considered in the base case,
and that there is little evidence to indicate that any form of
Doppler test is accurate enough to be cost effective for
early identification of pre-eclampsia. Meads et al. [26] did
perform a probabilistic sensitivity analysis, but there was
no report on model validation. There was no report on
discount rates either, but, given that the analysis only
covered the duration of the pregnancy, discounting was not
relevant. For the same reason, the choice of a decision tree
seems suitable. A rather serious drawback of the analysis,
which was also mentioned by the authors in their discus-
sion, is that all tests were considered separately, using their
stand-alone accuracy. Even though combinations of tests,
as well as combinations of tests and clinical judgment,
would probably be more accurate and also more reflective
of clinical practice than using one test by itself, there was
no evidence regarding the sensitivity and specificity of
these combinations; therefore, they could not be incorpo-
rated into the model. Given this limitation, the importance
of the cost-effectiveness results was confined to the context
of single testing only.
Table 2 Categories of included costs in economic evaluation of screening, diagnosis, treatment and prevention for pre-eclampsia
Study Categories of included costs Currency, price
year
Screening and diagnosis
Shmueli
[27]
Screening test cost, supplement and medication cost, cost of visit frequency, cost of prenatal care, pre-
delivery hospitalization, maternal and neonatal costs, offspring’s lifetime costs considering 30-year
follow-up
Price year not
mentioned
Meads
[26]
Test costs (body mass index measurements, maternal serum a-fetoprotein, cellular fibronectin, total
fibronectin, fetal DNA, maternal serum human chorionic gonadotropin, serum unconjugated oestriol,
serum uric acid, urinary calcium excretion, urinary calcium creatinine ratio, total proteinuria, albuminuria,
microalbuminuria, albumin/creatinine ratio, Doppler examinations), treatment costs (antioxidants,
calcium, garlic, magnesium, fish oils, medications [antihypertensive, antiplatelet, diuretic, nitric oxide,
progesterone]), intervention costs, pre-eclampsia costs (including all hospital costs for mother and baby,
without costs of normal delivery)
GBP, 2005–2006
Hadker
[25]
Pre-eclampsia assessment costs, drug costs, pre-eclampsia management costs (physician office visits,
physical exams, regular blood pressure checks, blood and urine tests and cardiotocography, as well as
hospital stays for day assessments, intensive care, inpatient monitoring and delivery or termination of
pregnancy), cost of the novel test, and cost of all testing
Price year not
mentioned
Treatment
Vijgen
[29]
Direct medical costs: hospital stay (mother and child), specialist care, outpatient visit, psychologist,
midwife, general practitioner, paramedical, home care, day care, induction methods, medications
(antihypertensive medication and antibiotics, analgesics during labour), neonatal monitoring, operation
room, labour room. Direct non-medical costs: modes of travelling to hospital and use of informal care
given by partner or family. Indirect medical costs: sick leave from work
EUR, 2007
Simon
[28]
Total cost was calculated as the sum of treatment and other costs. Treatment cost included magnesium
sulphate and its administration (staffing, equipment, consumables). Other costs covered all other aspects of
hospital care in the trial, such as treating pre-eclampsia, eclampsia, and side effects of magnesium sulphate
treatment; and costs of antenatal and postnatal ward stay, high dependency and/or intensive care, artificial
ventilation, delivery and medication for the mother and the costs of the hospital stay, neonatal intensive
care and artificial ventilation for the baby
USD, 2001
Blackwell
[30]
Drug cost, pharmacy personnel time charges Price year not
mentioned
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Another study on screening was a BIA by Hadker et al.
[25], which analysed the financial consequences, in the UK
setting, of implementing a novel biomarker test for pre-
eclampsia. As a BIA is applied to a specific health care set-
ting, it is recommended that the data sources represent the
circumstances in the setting [22]. The clinical data of the
includedBIA studywere derived from the relevant literature,
as well as local UK databases and interviews. The test under
investigation consisted of two biomarkers, PIGF and sFlt-1,
and was assumed to have a sensitivity of 82 % and a speci-
ficity of 95 % after 20 weeks of gestation, as calculated from
a multicentre case–control study [36]. The novel test was
compared with current practice, which included blood tests
such as serumuric acid, urine tests (to screen for proteinuria),
blood pressure measurements and uterine artery Doppler
ultrasounds. Accuracy estimates for the diagnostic tests
performed in current practice were taken from Meads et al.
[26]. The time horizon of the model was from the booking
period (12 weeks) to term (40 weeks). Because of the
improved sensitivity and specificity of the novel test, false
positives were reduced, while true positives were increased.
Even though the novel test increased test costs, treatment
costs were reduced because there were fewer false positive
patients who received unnecessary management and also
fewer false negative patients who were not treated properly
and would therefore incur costs later on. From the hypo-
thetical cohort of 1000 pregnant women, it was estimated
that in summary, the novel test was cost saving compared
with standard practice [25].
3.2.2 Studies on Treatment
The other three studies included in the review were on the
topic of treatment for pre-eclampsia. The study by Vijgen
et al. [29] was conducted alongside the Dutch Hypertension
and Pre-eclampsia Intervention Trial at Term (HYPITAT)
trial [37] and evaluated the economic consequences of
delivery induction compared with expectant monitoring in
women with mild pre-eclampsia at term. In the trial,
women with gestational hypertension or pre-eclampsia
between 36 and 41 weeks of gestation were randomly
allocated to either expectant monitoring (n = 379) or
induction of delivery (n = 377). In the expectant-moni-
toring group, patients were monitored until spontaneous
delivery, whereas in the induction group, delivery was
induced within 24 h after randomization. The CEA was
performed from a societal perspective, i.e. including pro-
ductivity costs. The results showed that induction of
Table 3 Main findings (values are expressed in 2014 USD)
Study Main findings
Screening and diagnosis approaches
Shmueli [27] From a payer perspective, screening for pre-eclampsia is cost effective under various scenarios
The incremental cost per pre-eclampsia case averted is $68,973 (prevalence 1.7 %)
Early screening: $19,491 per QALY gained (prevalence 1.7 %)
With a test cost of $115, the total cost until discharge with/without screening is equal; at a prevalence of 3%, screening is
cheaper
Meads [26] From a decision maker viewpoint, giving calcium supplementation to all pregnant women (‘no test/calcium all)’ without any
initial testing is the most effective ‘test/treatment’ combination
Hadker [25] The model estimated that the costs of a typical pregnancy are $2919 per patient when the new test is used, as compared with
$4468 without the test (standard practice); this represents savings of $1549 per pregnant woman; the savings are attributed to
the new test’s improved accuracy
Treatment approaches
Vijgen [29] From a societal point of view, induction of delivery is cost effective compared with expectant monitoring in term pre-eclampsia;
induction does not result in a higher rate of caesarean section, while fewer patients progress to severe disease
Simon [28] From a hospital perspective, use of magnesium sulphate prevents more cases of eclampsia in low-GNI countries than in high-
GNI countries
High-GNI countries: $28,335 per case of eclampsia prevented
Middle-GNI countries: $3,305 per case of eclampsia prevented
Low-GNI countries: $609 per case of eclampsia prevented
Also, treating only severe cases of pre-eclampsia substantially lowers the ICER, i.e. has a more favourable cost-to-effect ratio
Blackwell
[30]
Universal prophylaxis using magnesium sulphate for all women with pre-eclampsia is cost effective compared with the strategy
of treating only those with severe disease; ICER for universal compared with selected strategy: $13,356 per seizure prevented
and $626,782 per death averted, which is considered cost effective assuming 1 death averted saves on average 30 life-years
and given a threshold of $50,000 per life-year gained
GNI gross national income, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
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delivery was less costly than expectant monitoring, mostly
because of the differences in resource use in the antepartum
period. As the HYPITAT trial had already demonstrated
that induction of labour results in less progression to severe
disease but does not increase the rate of caesarean sections,
both costs and effectiveness were more favourable in the
induction group. Induction of labour was also least
expensive in all of the sensitivity analyses that were per-
formed. The HYPITAT trial [37] was a Dutch study, and
since the Dutch model for pregnancy care is rather unique
[38], the conclusions of this trial may not hold in other
countries and health care systems, i.e. the population with
gestational hypertension or pre-eclampsia referred for
secondary care in the Netherlands may not be representa-
tive of the global or European situation.
The other two included studies assessed the use of mag-
nesium sulphate. Simon et al. [28] evaluated cost effective-
ness alongside the large international Magnesium Sulphate
for Prevention of Eclampsia (Magpie) trial, which compared
magnesium sulphate with placebo in 9996 women with pre-
eclampsia in 333 countries [39]. Patients included in the
study were randomly allocated to receive either a placebo or
magnesium sulphate (intramuscularly or intravenously, at
the discretion of the physician). The CEA was performed
from a hospital perspective and distinguished between high-,
middle- and low-income countries. The costs included in the
analysis were the costs of treatment (magnesium sulphate
and its administration) and ‘other’ costs for treating pre-
eclampsia, eclampsia or the side effects of magnesium sul-
phate treatment. The study showed that in low–gross national
income (GNI) countries, magnesium sulphate averts more
eclampsia than in high-GNI countries, because in low-GNI
countries, the baseline prevalence of pre-eclampsia is higher,
which increases the absolute risk reduction. Therefore,
magnesium sulphate for pre-eclampsia was found to be most
cost effective in low-income countries. In addition, cost
effectiveness would be considerably improved in all income
categories if only severe pre-eclampsia was treated with
magnesium sulphate, or if the purchase price in low-income
countries could be reduced. The Magpie trial [39] was per-
formed in many countries, with almost complete follow-up
([99 %), and reported the CEA separately for low-, middle-
and high-income countries, facilitating translation to other
settings.
Blackwell et al. [30] also evaluated the cost effective-
ness of magnesium sulphate in pregnancies complicated by
pre-eclampsia, by means of a decision model comparing
three strategies, i.e. no anticonvulsant therapy, selective
prophylaxis for patients with severe pre-eclampsia and
universal prophylaxis for all patients with pre-eclampsia.
The clinical consequences were described as development
of eclampsia or maternal death associated with eclampsia,
and cost effectiveness was expressed as the cost per seizure
averted and the cost per maternal death averted. The
authors chose to use a decision tree, which seems perfectly
appropriate. Inputs for the model were derived from the
literature available at the time, which did not yet include
the results of the Magpie trial. The analysis was performed
for the US setting. Costs included in the model seemed to
be limited to the cost of magnesium sulphate injections and
associated personnel time for administration. So the pos-
sible cost consequences due to treating seizures or the side
effects of magnesium sulphate, for example, were not
considered. Given this information, the perspective of the
economic evaluation was not clear, because the authors did
not explicitly state what the perspective was, and only
some of the hospital costs were taken into account. The
authors argued that universal treatment of all women with
pre-eclampsia is a more cost-effective option than the
selective strategy. Even though the incremental cost
effectiveness resulting from the analysis was substantial, it
would still be below the threshold of $50,000 per life-year
gained if one assumes that one death averted equals 30 life-
years gained. In this calculation, costs were discounted at
3 %, but the effects were not, which may be considered
questionable given the guidelines on this [40]. Probabilistic
sensitivity analysis was not performed. The input param-
eters were varied in a univariate sensitivity analysis—but
solely to judge their impact on seizures and deaths averted,
not on cost effectiveness. For cost effectiveness, only the
impact of a change in the price of magnesium sulphate was
investigated, implicitly assuming that other parameters do
not matter in this respect, even though the efficacy of
magnesium sulphate had a significant impact on seizures
and deaths averted in both the universal treatment strategy
and the selective treatment strategy. Furthermore, the
impact of varying the price of magnesium sulphate on
incremental cost effectiveness was not clear from the
paper.
3.3 Assessment of Quality of Reporting
An overview of the appraisal of the reporting format for all
included studies is presented in Table 4. The issues on
which the studies complied least with the recommendations
of both CHEERS and the BIA reporting format mostly
concerned methods. The discount rate for both costs and
outcomes (item 9), measurement of effectiveness (items
11a and 11b), measurement and valuation of preference-
based outcomes (item 12), estimation of resources and
costs (items 13a and 13b), rationale for choice of decision-
analytical model type (item 15) and description of analyt-
ical methods supporting the evaluation (such as extrapo-
lation methods, approaches to validate the model, etc.)
(item 17) appeared to be the items that were frequently
only partially reported or were not reported at all. In
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addition, the justification of the choice of comparator,
study perspective and time horizon were not reported in
some studies. In the BIA study, input data items were only
partially reported. In addition, a discussion of strengths,
weaknesses and possible sources of bias that might have
been inherent in the data used in the analysis, as well as a
description of methods and processes for primary data
collection and data abstraction, were not present in the
included BIA study.
Incremental costs and outcomes and study findings, both
in results and discussion sections, were generally reported
in all studies, as summarized in Table 3. However, some
studies did not provide a discussion of the limitations and
generalizability of their findings. Almost all studies stated
their source of funding. Nevertheless, only half of the
studies reported on conflicts of interest.
Most of the studies were published in obstetrics and
gynaecology journals [27–30], and one study was pub-
lished in a health economic journal [25], whereas the study
by Meads et al. [26] was—as was inherent in the nature of
the research project—published as an HTA report.
4 Discussion
A systematic review was conducted to provide an overview
of published health economics studies in screening, diag-
nosis, treatment options and prevention of pre-eclampsia.
In this review, we found five relevant and retrievable
economic evaluation studies and one BIA study. This
review provides a comprehensive insight into the economic
aspects of pre-eclampsia, from screening to treatment
choices. We used the most recent guidelines on economic
evaluation and BIA, which provide comprehensive rec-
ommendations to assess such studies. To the best of our
knowledge, this is the first review to assess the health
economic implications of pre-eclampsia care. Given the
recent development of new interventions in the field of pre-
eclampsia, especially in screening and diagnosis, the
results of our study are of importance to decision makers
and can support the evaluation of health care interventions
regarding pre-eclampsia care.
The conclusion provided by the included papers is that
screening pregnant women for pre-eclampsia has the
potential to be cost effective. Nevertheless, many uncer-
tainties remain. The evidence as to the accuracy of tests,
whether alone, in combination with each other, or in com-
bination with clinical judgment, is not strong enough to base
solid conclusions on. Two of the screening studies showed a
cost-effective screening strategy [25, 27], but in both of these
studies the evidence base for the accuracy parameters used in
the model was limited. Shmueli et al. [27] derived the
detection rate from a study by Akolekar et al. [31], who, inT
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turn, derived results partly directly from a trial, but for a
number ofmarkers they used data fromother studies. In other
words, the detection rates used in the cost-effectiveness
model have never been observed in a real population using
these specific markers. Hadker et al. [25] derived accuracy
estimates from a case–control study with 71 pre-eclampsia
cases and 268 healthy controls [36], which may be perfectly
valid. However, the accuracy of the comparator, or care as
usual, is obtained by calculating an average of the sensitivity
and specificity of all tests, as reported in the HTA report by
Meads et al. [26]. This may introduce bias, as Meads et al.
reported on 25 different tests, some of which are admittedly
not very good at detecting pre-eclampsia and probably are
not part of current care as usual. In addition, as was also
explicitly mentioned by Meads et al., their definition of test
accuracy applied to single testing, which is not a typical
representation of care as usual. Taking these two points
together, the pooled accuracy fromMeads et al. is likely to be
an underestimation of test accuracy in clinical practice,
whichwould result in an overly optimistic view of the budget
impact of the novel test.
As for treatment options, the case for induction of labour
seems strong compared with expectant monitoring in
women with term pre-eclampsia, concerning both effec-
tiveness and cost effectiveness. For the use of magnesium
sulphate, the findings are slightly more complicated, as
Simon et al. [28] found that the use of magnesium sulphate
is particularly cost effective in severe cases of pre-
eclampsia, whereas Blackwell et al. [30] concluded quite
the opposite, i.e. that it is more cost effective to treat all
women with pre-eclampsia with magnesium sulphate,
without considering severity. It is difficult to explain this
contradiction, although a possible reason for the difference
may lie in the perspectives taken for calculating the costs.
Blackwell et al. only took account of the costs of the
magnesium sulphate itself plus the costs of its adminis-
tration, while Simon et al. took a slightly broader per-
spective and included all hospital costs associated with
magnesium sulphate treatment but also with pre-eclampsia
per se. This broader perspective may have identified a cost
advantage for the group with severe pre-eclampsia in the
analysis by Simon et al. That said, the two studies differed
in many other respects, and the differences may have been
due to the study setting and approaches used to assess
resources and costs, as well as the sources of clinical
effectiveness data for the analysis.
Regarding the quality of the reporting format for both
economic evaluation and BIA studies, we noticed that there
were shortcomings in the reporting of details of the
methods used in most of the studies. Reporting could also
be improved in the introduction section by provision of an
explanation or justification for the choice of economic
evaluation used in relation to addressing the research
questions. Also, a description of values, ranges and refer-
ences for all parameters and their rationales should be
provided in the results section, while each discussion sec-
tion needs debate on the generalizability of the findings.
Although insufficient reporting does not necessarily reflect
inadequate study quality, the availability of recommenda-
tions such as the CHEERS statement [24] and the BIA
Principles of Good Practice for Budget Impact Analysis
[22] could be used to improve the reporting quality and
thus lead to improved evaluation, transparency and com-
parability in economic evaluation and BIA studies.
There are several limitations of our review, which lie
mainly in the limited number of papers we were able to
include, and in the large variety of topics studied and
methods used. There were five CEAs and one BIA; four
studies were model based and two were trial based; three
studies were on some form of screening, two studies were
on magnesium sulphate and one was on labour induction in
term pre-eclampsia. Besides this, there were vast differ-
ences among the included studies concerning the alterna-
tives compared, time horizons and perspectives of the
analyses, and the ways in which sensitivity analyses were
performed. Therefore, it was not possible to make valid
comparisons between studies or draw general conclusions,
and so it remains uncertain whether screening for pre-
eclampsia and subsequent prophylactic treatment can be
considered cost effective. It seems that, in any case, the
currently available screening techniques are not quite
accurate enough and lack predictive power in a clinical
setting. The two studies on magnesium sulphate were
equivocal in their conclusions on the cost effectiveness of
also treating non-severe cases of pre-eclampsia. In addi-
tion, even though our review was as up to date as possible,
it did not include any economic evaluation studies on
prophylactic aspirin, which has been added to the National
Institute for Health and Care Excellence (NICE) guidelines
and is recommended by the WHO [18, 41]. Park et al. [42]
showed that prescribing aspirin (150 mg daily) to pregnant
women at high risk of developing early-onset pre-
eclampsia could significantly reduce the number of cases.
Given the fact that aspirin is inexpensive and conveniently
taken, it may very well be a cost-effective option, and this
will probably become apparent in the near future.
Individual interpretation of the recommendations could
also be a potential limitation for our review. We used ‘yes’
(Y), ‘no’ (N), ‘partially reported’ (P), and ‘not applicable’
(NA) to assess the quality of reporting, which was based on
the interpretation of the reviewers. The ‘partially reported’
category was necessary because some items in the checklist
consisted of multiple recommendations. For instance, in
item 17 (‘analytical methods’) from the CHEERS state-
ment, the recommendation was to describe all analytical
methods supporting the evaluation, including methods for
Pre-eclampsia Diagnosis and Treatment Options: A Review 1079
dealing with skewed, missing or censored data, extrapola-
tion methods, methods for pooling data, approaches to
validate or make adjustments to a model, and methods for
handling population heterogeneity and uncertainty—and if
the study did not provide one of these, then the item was
scored as partially reported. This was subject to bias,
however, as the difference between fully reported (Y) and
partially reported (P) was not always clear.
Importantly, the consequences of pre-eclampsia are not
limited to early life; surviving offspring are at much greater
risk of cerebral palsy and neurodevelopmental delay, and
have increased risks of obesity, cardiovascular disease,
hypertension, diabetes and schizophrenia in adulthood [43–
49]. Global rates of these conditions have increased rapidly
[50] and impose massive burdens on public health systems,
the economy and society [51, 52]. These burdens will rise
further with the trend of decreasing age at disease onset, as
evidenced by the increasing prevalence of childhood and
adolescent obesity, diabetes, hypertension and car-
diometabolic risk factors [53, 54]. The International
Monetary Fund (IMF), World Bank, WHO and United
Nations (UN) all indicate the need for greater emphasis on
maternal and infant health [55, 56].
5 Conclusion
Novel biomarkers in screening for and diagnosing pre-
eclampsia show promise, but their accuracy is a major
driver of cost effectiveness, as is prevalence. Universal
screening for pre-eclampsia using a biomarker will be
feasible only when accuracy is significantly increased. In
addition, the included studies identified the need for more
research into—among other things—the long-term conse-
quences of pre-eclampsia, accuracy of combinations of
tests/accuracy of tests integrated into a clinical decision
rule, and effectiveness of prophylactic treatment strategies.
Improvement in the quality of reporting, especially in the
methods used, for further economic evaluation studies of
diagnosis and treatment options for pre- eclampsia is also
needed.
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